Athos Capital Ltd bought a new position in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 284,200 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,126,000. SciClone Pharmaceuticals accounts for about 1.8% of Athos Capital Ltd’s portfolio, making the stock its 16th largest position.

Several other institutional investors also recently modified their holdings of the company. LS Investment Advisors LLC increased its position in shares of SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 8,355 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,320 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of SciClone Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 10,213 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 4,503 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 310 shares in the last quarter. Finally, Mason Street Advisors LLC increased its position in shares of SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 881 shares in the last quarter. Institutional investors and hedge funds own 71.84% of the company’s stock.

SciClone Pharmaceuticals, Inc. (NASDAQ SCLN) opened at 11.05 on Thursday. SciClone Pharmaceuticals, Inc. has a one year low of $8.55 and a one year high of $11.43. The stock’s 50 day moving average price is $10.97 and its 200-day moving average price is $10.14. The stock has a market cap of $571.64 million, a P/E ratio of 15.54 and a beta of 1.71.

TRADEMARK VIOLATION NOTICE: “Athos Capital Ltd Takes Position in SciClone Pharmaceuticals, Inc. (SCLN)” was first posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.watchlistnews.com/athos-capital-ltd-takes-position-in-sciclone-pharmaceuticals-inc-scln/1470331.html.

Separately, Maxim Group set a $14.00 price target on SciClone Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, May 11th.

In related news, CEO Friedhelm Blobel sold 70,000 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $10.91, for a total value of $763,700.00. Following the completion of the sale, the chief executive officer now owns 152,209 shares in the company, valued at approximately $1,660,600.19. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the completion of the sale, the chief financial officer now owns 14,372 shares of the company’s stock, valued at approximately $154,499. The disclosure for this sale can be found here. In the last 90 days, insiders sold 235,500 shares of company stock valued at $2,479,764. 5.16% of the stock is owned by corporate insiders.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.